CLOVIS ONCOLOGY INC's ticker is and the CUSIP is 189464AB6. A total of 30 filers reported holding CLOVIS ONCOLOGY INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $22,019,000 | -13.1% | 24,758,000 | -9.3% | 0.43% | -23.8% |
| Q1 2019 | $25,344,000 | +62.6% | 27,289,000 | +47.4% | 0.56% | +48.3% |
| Q4 2018 | $15,585,000 | -35.5% | 18,512,000 | -28.3% | 0.38% | -24.3% |
| Q3 2018 | $24,147,000 | +145.7% | 25,827,000 | +182.9% | 0.50% | +140.6% |
| Q2 2018 | $9,826,000 | -9.2% | 9,129,000 | -1.6% | 0.21% | -2.8% |
| Q1 2018 | $10,824,000 | +9.3% | 9,279,000 | +26.6% | 0.21% | +12.1% |
| Q4 2017 | $9,903,000 | -10.4% | 7,328,000 | +2.8% | 0.19% | -9.1% |
| Q3 2017 | $11,056,000 | -16.7% | 7,131,000 | -8.9% | 0.21% | -17.7% |
| Q2 2017 | $13,277,000 | -50.0% | 7,826,000 | -62.0% | 0.25% | -48.8% |
| Q1 2017 | $26,533,000 | +13.3% | 20,585,000 | -9.4% | 0.50% | +15.1% |
| Q4 2016 | $23,415,000 | +323.4% | 22,721,000 | +291.5% | 0.43% | +438.8% |
| Q3 2016 | $5,530,000 | -41.7% | 5,803,000 | -47.2% | 0.08% | -45.2% |
| Q4 2015 | $9,492,000 | -43.1% | 11,000,000 | +10.0% | 0.15% | -42.7% |
| Q3 2015 | $16,669,000 | – | 10,000,000 | – | 0.26% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| LINDEN ADVISORS LP | 69,346,000 | $107,321,000 | 3.81% |
| PFM Health Sciences, LP | 34,710,000 | $53,670,000 | 1.06% |
| Partner Investment Management, L.P. | 556,000 | $860,000 | 0.82% |
| Myriad Asset Management Ltd. | 5,000,000 | $7,731,000 | 0.75% |
| SYMPHONY ASSET MANAGEMENT LLC | 4,000,000 | $6,185,000 | 0.69% |
| CAPSTONE INVESTMENT ADVISORS, LLC | 9,074,000 | $14,030,000 | 0.49% |
| CSS LLC/IL | 5,251,000 | $8,112,000 | 0.40% |
| SSI INVESTMENT MANAGEMENT LLC | 2,813,000 | $4,333,000 | 0.37% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 7,131,000 | $11,056,000 | 0.21% |
| D. E. Shaw & Co., Inc. | 27,750,000 | $42,835,000 | 0.07% |